HIV-VAC'S Dr. Gordon Skinner Discusses AIDS Vaccine Potential to Halt Rising Worldwide Death Toll.Business Editors, Health/Medical Writers TORONTO--(BUSINESS WIRE)--Jan. 27, 2000 HIV-VAC, Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :HIVC) today announced that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG FRCOG Fellow of the Royal College of Obstetricians and Gynaecologists , FRCPath, the developer of the Skinner HIV-VAC AIDS vaccine AIDS vaccine A hypothetical vaccine intended to either prevent HIV infection or ensure that those infected will not fall victim to AIDS; the most promising vaccine is that using a naked DNA plasmid, reported by Letwin et al in 20/10/00 Science; as of early 2001, , was interviewed by WebMd to discuss the vaccine's potential to end the worldwide AIDS epidemic. Dr. Skinner's interview with WebMD can be heard by accessing Hiv-Vac's website at the Internet address There are two kinds of addresses that are widely used on the Internet. One is a person's e-mail address, and the other is the address of a Web site, which is known as a URL. Following is an explanation of Internet e-mail addresses only. For more on URLs, see URL and Internet domain name. : www.hivvac.com Unlike other AIDS vaccines currently under development, the Skinner HIV-VAC AIDS vaccine is based on a new and very unique approach to neutralizing the AIDS virus AIDS virus n. See HIV. that has the potential to be effective with the AIDS virus' many mutant forms. This technology is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus cytomegalovirus (sī'təmĕg'əlōvī`rəs), member of the herpesvirus family that can cause serious complications in persons with weakened immune systems. and equine herpes vaccines. This has been under development by Dr. Skinner and his team for the past 10 years at the University of Birmingham Due to Birmingham's role as a centre of light engineering, the university traditionally had a special focus on science, engineering and commerce, as well as coal mining. It now teaches a full range of academic subjects and has five-star rating for teaching and research in several , United Kingdom. Pre-clinical testing of the Skinner HIV-VAC AIDS vaccine is nearing completion, with Phase I &II testing taking place in Russia at the Russia Aids Centre. The Russian phase of the vaccine development program will be headed up by Dr. Vadim Pokrovsky at the Russia Aids Centre, which has particular expertise in immune pathology and evaluation of efficacy and safety testing of vaccines. The United Nations estimates that there are currently 33 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million. Sales of anti-HIV drugs increased to more than $3 billion last year and could reach $6 billion in coming years. The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion